Development of soybean protein-based bioactive substances delivery systems: a systematic overview based on recent researches
Maintaining weight after GLP-1 treatment is one of the most challenging phases of the journey
CrossRef Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan Frontiers in Nutrition .2025;[Epub] CrossRef The Unequal Burden of Metabolic DysfunctionAssociated Steatotic Liver Disease in 204 Countries and Territories From 1990 to 2021 Junqiao Feng, Yudan Fan Liver International .2025;[Epub] CrossRef Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs Nicola Pugliese, Davide Polverini, Stefano Ciardullo Liver International .2025;[Epub] CrossRef MultiCenter, MultiVendor Validation of Simultaneous MRIBased Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat FractionR2* Phantom Jitka Starekova, David Rutkowski, Won C

Manufacturers Responsibility to Warn of Potential Risks Drug manufacturers are obligated to disclose known and reasonably foreseeable risks associated with their medications
Do not use it if it looks cloudy, discolored, frozen, or has floating particles
Likewise, LUCAT1, a newly discovered lncRNA, is often upregulated in lung and other cancers, and its inhibition markedly impedes tumor proliferation both in vitro and in vivo 20,21,22